155 related articles for article (PubMed ID: 32501650)
1. Estimation of Equipotent Doses for Anti-Inflammatory Effects of Prednisolone and AZD9567, an Oral Selective Nonsteroidal Glucocorticoid Receptor Modulator.
Almquist J; Sadiq MW; Eriksson UG; Hegelund Myrbäck T; Prothon S; Leander J
CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):444-455. PubMed ID: 32501650
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile.
Ripa L; Edman K; Dearman M; Edenro G; Hendrickx R; Ullah V; Chang HF; Lepistö M; Chapman D; Geschwindner S; Wissler L; Svanberg P; Lawitz K; Malmberg J; Nikitidis A; Olsson RI; Bird J; Llinas A; Hegelund-Myrbäck T; Berger M; Thorne P; Harrison R; Köhler C; Drmota T
J Med Chem; 2018 Mar; 61(5):1785-1799. PubMed ID: 29424542
[TBL] [Abstract][Full Text] [Related]
3. Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials.
Hegelund Myrbäck T; Prothon S; Edman K; Leander J; Hashemi M; Dearman M; Edenro G; Svanberg P; Andersson EM; Almquist J; Ämmälä C; Hendrickx R; Taib Z; Johansson KA; Berggren AR; Keen CM; Eriksson UG; Fuhr R; Carlsson BCL
Lancet Rheumatol; 2020 Jan; 2(1):e31-e41. PubMed ID: 38258274
[TBL] [Abstract][Full Text] [Related]
4. AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double-blind, efficacy, and safety study.
van Laar JM; Lei A; Safy-Khan M; Almquist J; Belfield G; Edman K; Öberg L; Angermann BR; Dillmann I; Berntsson P; Etal D; Dainty I; Astbury C; Belvisi MG; Nemes S; Platt A; Prothon S; Samuelsson S; Svanberg P; Keen C;
Clin Transl Sci; 2023 Dec; 16(12):2494-2506. PubMed ID: 37873558
[TBL] [Abstract][Full Text] [Related]
5. Clinical profile of the functionally selective glucocorticoid receptor agonist BI 653048 in healthy male subjects.
Harcken C; Scholl P; Nabozny G; Thomson D; Bianchi D
Expert Opin Investig Drugs; 2019 May; 28(5):489-496. PubMed ID: 30908082
[TBL] [Abstract][Full Text] [Related]
6. The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial.
Ambery P; Zajac G; Almquist J; Prothon S; Astbury C; Brown MN; Nemes S; Nsabimana J; Edman K; Öberg L; Lepistö M; Edenro G; Dillmann I; Mitra S; Belfield G; Keen C; Heise T
Br J Clin Pharmacol; 2024 May; ():. PubMed ID: 38690606
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel isoxazoline derivative of prednisolone endowed with a robust anti-inflammatory profile and suitable for topical pulmonary administration.
Ghidini E; Capelli AM; Carnini C; Cenacchi V; Marchini G; Virdis A; Italia A; Facchinetti F
Steroids; 2015 Mar; 95():88-95. PubMed ID: 25556984
[TBL] [Abstract][Full Text] [Related]
8. The preclinical efficacy, selectivity and pharmacologic profile of MK-5932, an insulin-sparing selective glucocorticoid receptor modulator.
Brandish PE; Anderson K; Baltus GA; Bai C; Bungard CJ; Bunting P; Byford A; Chiu CS; Cicmil M; Corcoran H; Euler D; Fisher JE; Gambone C; Hasbun-Manning M; Kuklin N; Landis E; Lifsted TQ; McElwee-Witmer S; McIntosh IS; Meissner RS; Miao J; Mitchell HJ; Musselman A; Schmidt A; Shin J; Szczerba P; Thompson CD; Tribouley C; Vogel RL; Warrier S; Hershey JC
Eur J Pharmacol; 2014 Feb; 724():102-11. PubMed ID: 24374007
[TBL] [Abstract][Full Text] [Related]
9. Suppression of human monocyte tumour necrosis factor-alpha release by glucocorticoid therapy: relationship to systemic monocytopaenia and cortisol suppression.
Steer JH; Vuong Q; Joyce DA
Br J Clin Pharmacol; 1997 Apr; 43(4):383-9. PubMed ID: 9146850
[TBL] [Abstract][Full Text] [Related]
10. 5-Functionalized indazoles as glucocorticoid receptor agonists.
Bai M; Carr G; Deorazio RJ; Friedrich TD; Dobritsa S; Fitzpatrick K; Guzzo PR; Kitchen DB; Lynch MA; Peace D; Sajad M; Usyatinsky A; Wolf MA
Bioorg Med Chem Lett; 2010 May; 20(10):3017-20. PubMed ID: 20427184
[TBL] [Abstract][Full Text] [Related]
11. Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug.
Zimmermann GR; Avery W; Finelli AL; Farwell M; Fraser CC; Borisy AA
Arthritis Res Ther; 2009; 11(1):R12. PubMed ID: 19171052
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacodynamic effects of deflazacort and prednisolone in healthy subjects.
Babadjanova G; Allolio B; Vollmer M; Reincke M; Schulte HM
Eur J Clin Pharmacol; 1996; 51(1):53-7. PubMed ID: 8880052
[TBL] [Abstract][Full Text] [Related]
13. Selective glucocorticoid receptor modulation inhibits cytokine responses in a canine model of mild endotoxemia.
Bartko J; Derhaschnig U; Neels T; Nabozny GH; Harcken C; Leuschner J; De Vries F; Jilma B
Pharmacol Res; 2017 Nov; 125(Pt B):215-223. PubMed ID: 28923543
[TBL] [Abstract][Full Text] [Related]
14. Differential in vivo effects on target pathways of a novel arylpyrazole glucocorticoid receptor modulator compared with prednisolone.
Roohk DJ; Varady KA; Turner SM; Emson CL; Gelling RW; Shankaran M; Lindwall G; Shipp LE; Scanlan TS; Wang JC; Hellerstein MK
J Pharmacol Exp Ther; 2010 Apr; 333(1):281-9. PubMed ID: 20065017
[TBL] [Abstract][Full Text] [Related]
15. JTP-117968, a novel selective glucocorticoid receptor modulator, exhibits significant anti-inflammatory effect while maintaining bone mineral density in mice.
Kurimoto T; Tamai I; Nakagawa T; Miyai A; Yamamoto Y; Kosugi Y; Deai K; Hata T; Ohta T; Matsushita M; Yamada T
Eur J Pharmacol; 2021 Mar; 895():173880. PubMed ID: 33476654
[TBL] [Abstract][Full Text] [Related]
16. Predicting Exposure After Oral Inhalation of the Selective Glucocorticoid Receptor Modulator, AZD5423, Based on Dose, Deposition Pattern, and Mechanistic Modeling of Pulmonary Disposition.
Bäckman P; Tehler U; Olsson B
J Aerosol Med Pulm Drug Deliv; 2017 Apr; 30(2):108-117. PubMed ID: 27740878
[TBL] [Abstract][Full Text] [Related]
17. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
Gotzsche PC; Johansen HK
Cochrane Database Syst Rev; 2004; 2005(3):CD000189. PubMed ID: 15266426
[TBL] [Abstract][Full Text] [Related]
18. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
Gotzsche PC; Johansen HK
Cochrane Database Syst Rev; 2003; (1):CD000189. PubMed ID: 12535392
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and local anti-inflammatory activity of 17β-carboxamide derivatives of glucocorticoids.
Dobričić V; Marković B; Milenković N; Savić V; Jaćević V; Rančić N; Vladimirov S; Cudina O
Arch Pharm (Weinheim); 2014 Nov; 347(11):786-97. PubMed ID: 25159891
[TBL] [Abstract][Full Text] [Related]
20. Differences in down-regulation of glucocorticoid receptor mRNA by cortisol, prednisolone and dexamethasone in HeLa cells.
Shimojo M; Hiroi N; Yakushiji F; Ueshiba H; Yamaguchi N; Miyachi Y
Endocr J; 1995 Oct; 42(5):629-36. PubMed ID: 8574285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
